source
- AbbVie says Skyrizi maintains strong sales momentum as competition risesAbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…
- AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectationsAbbVie’s stock fell about 4% on Friday after the company reported second‑quarter results that modestly exceeded analyst forecasts, disappointing investors who had set very high expectations. The f…